Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
Open Access
- 15 January 2010
- Vol. 116 (5), 1234-1242
- https://doi.org/10.1002/cncr.24816
Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) expression is associated with aggressive phenotypes in preclinical breast cancer models, but in clinical studies, EGFR has been inconsistently linked to poor outcome. We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy. METHODS: In a database of 47,286 patients with breast cancer, EGFR status was known on 2567 tumors. EGFR levels were measured centrally by ligand binding assay, and tumors with ≥10 fmol/mg were prospectively deemed positive. Clinical and biological features of EGFR‐positive and EGFR‐negative tumors were compared. Clinical outcomes were assessed by systemic therapy status. RESULTS: Of 2567 tumors, 475 (18%) were EGFR positive. EGFR‐positive tumors were more common in younger and in black women, were larger, had a higher S‐phase fraction, and were more likely to be aneuploid. EGFR‐positive tumors were more likely to be HER2‐positive (26% vs 16%, P < .0001), but less likely to be estrogen receptor‐positive (60% vs 88%, P < .0001) or progesterone receptor‐positive (26% vs 65%, P < .0001). In multivariate analyses, EGFR expression independently correlated with worse disease‐free survival (hazard ratio [HR] = 1.66; 95% confidence interval [CI], 1.4‐2.41, P = .007) and overall survival (HR = 1.98, 95% CI, 1.36‐2.88, P = .0004) in treated patients, but not in untreated patients. CONCLUSIONS: EGFR expression is more common in breast tumors in younger and black women. It is associated with lower hormone receptor levels, higher proliferation, genomic instability, and HER2 overexpression. It is correlated with higher risk of relapse in patients receiving adjuvant treatment. Blocking EGFR may improve outcome in selected patients. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 57 references indexed in Scilit:
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II StudyClinical Cancer Research, 2011
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- HER2 expression as a potential marker for response to therapy targeted to the EGFRBritish Journal of Cancer, 2006
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaLaboratory Investigation, 2005
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001